Jazz Pharmaceuticals Hits All the Right Notes in Q1
The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.
Wednesday, May 8, 2019
Jazz Pharmaceuticals Hits All the Right Notes in Q1
Jazz Pharmaceuticals Hits All the Right Notes in Q1
The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.
0 comments:
Post a Comment